SCHEDULE: Venrock Healthcare Discloses 4.6% Stake in CytomX

Venrock Healthcare Capital Partners and affiliates report a 4.6% beneficial ownership stake in CytomX Therapeutics, Inc. as of March 31, 2026.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P. collectively hold 9,982,124 shares of CytomX Therapeutics common stock.
• The reported ownership represents 4.6% of the total outstanding common stock of the issuer.
• The filing confirms that these shares are held for investment purposes and not to influence or change control of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming institutional interest without signaling a change in corporate strategy or control.

Positives

• Continued institutional investment from a specialized healthcare-focused venture capital firm.
• The reporting persons have certified that the holdings are passive in nature.

Negatives

• The aggregate ownership stake of 4.6% falls below the 5% threshold typically requiring more frequent or detailed disclosure updates.

Risks

• Market volatility associated with biotechnology equity investments.
• Potential dilution risks following the company's recent public offering of 45,990,567 shares in March 2026.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer, indicating a passive investment stance.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional portfolio management within the biotech sector, where venture capital firms often maintain significant but passive stakes in clinical-stage companies following public offerings.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for institutional investors holding significant minority positions.
• The disclosure of ownership percentages based on recent public offerings is consistent with transparent reporting practices for biotech equities.

Stakeholder Impact

• Provides transparency to shareholders regarding the concentration of institutional ownership.
• Confirms that major investors are maintaining their positions following the recent public offering.

Next Steps

• Continued monitoring of institutional ownership levels by the issuer.
• Potential future filings if ownership thresholds change significantly.

Key Dates

Keywords

CytomX Therapeutics, Venrock Healthcare, Schedule 13G, Biotechnology, Institutional Ownership, CTMX